DOSSIER · UPDATED 18 NOV 2025

Taysha Gene Therapies Inc

Taysha Gene Therapies is a developer of treatments to eradicate severe & life-threatening monogenic diseases of the central nervous system. Taysha Gene Therapies is on a mission to eradicate monogenic CNS disease. With a singular focus on…

tayshagtx.com ↗Claim this profile

Founded: 2020
Headcount: 101
Open roles: 0
Last raised: Post Ipo Equity · $200M

SECTION I · THE BRIEF

Inside Taysha Gene Therapies Inc

Brief #24765Updated 18 NOV 2025DALLASGVPOST IPO EQUITY

Employbl Dossier

Taysha Gene Therapies Inc

Taysha Gene Therapies is a developer of treatments to eradicate severe & life-threatening monogenic diseases of the central nervous system. Taysha Gene Therapies is on a mission to eradicate monogenic CNS disease. With…

Founded: 2020
Headcount: 101
Open roles: 0
Last raised: Post Ipo Equity · $200M

Section II — RestrictedMembers only

Engineering interview process at Taysha Gene Therapies Inc
Tech stack & infrastructure choices
Culture & day-to-day work style
Why join now vs. 6 months from now
Hiring focus & open headcount by team
Comp philosophy and band context

Open Taysha Gene Therapies Inc brief Sign in

7-day free trial · $25/mo · cancel anytime

LEADERSHIP

Founders & key people

R.A. Session II

OPEN ROLES

Hiring at Taysha Gene Therapies Inc

Current Job Listings

Listing 0 of 0 job openings

We don't currently have any jobs listed for this company. We suggest visiting the Jobs Search page if you are looking for exciting new tech and startup opportunities.

FUNDING

Capital raised

Total Amount Raised: $743,000,000

Taysha Gene Therapies Inc's Investors

Taysha Gene Therapies Inc Funding Rounds

Post Ipo Equity
$200,000,000
May 28, 2025
Post Ipo Equity
$200,000,000
May 27, 2025
Post Ipo Equity
$75,000,000
Jun 26, 2024
Post Ipo Equity
$75,000,000
Jun 25, 2024
Post Ipo Debt
$40,000,000
Dec 19, 2023
Post Ipo Debt
$40,000,000
Dec 18, 2023
Post Ipo Debt Investors
Trinity Capital
Post Ipo Equity
$150,000,000
Aug 14, 2023
Post Ipo Equity
$150,000,000
Aug 13, 2023
Post Ipo Equity Investors
RA Capital Management
Invus Group
PBM Capital Group
GordonMD Global Investments
RTW Investments
Acuta Capital Partners
Venrock Healthcare Capital Partners
Octagon Capital Advisors
TCG Crossover Management
B Capital
Kynam Capital Management
Post Ipo Equity
$3,000,000
Nov 3, 2022
Post Ipo Equity
$3,000,000
Nov 2, 2022
Post Ipo Equity
$50,000,000
Oct 24, 2022
Post Ipo Equity
$50,000,000
Oct 23, 2022
Post Ipo Equity Investors
Astellas Pharma
Post Ipo Debt
$100,000,000
Aug 16, 2021
Post Ipo Debt
$100,000,000
Aug 15, 2021
Post Ipo Debt Investors
First Citizens Bank
Series B
$95,000,000
Aug 5, 2020
Series B
$95,000,000
Aug 4, 2020
Series B Investors
Fidelity Investments
PBM Capital Group
Invus Group
Casdin Capital
GV
Sands Capital Management
Venrock Healthcare Capital Partners
ArrowMark Partners
Franklin Resources, Inc.
Perceptive Advisors
BlackRock
Nolan Capital
Octagon Capital Advisors
Seed
$30,000,000
Apr 29, 2020
Seed
$30,000,000
Apr 28, 2020
Seed Investors
Nolan Capital
PBM Capital Group
IPO
Unknown
Jan 1, 2020

Funding info provided by Diffbot.

TAGS

Categorized in

Company Collections

These are collections Taysha Gene Therapies Inc is a part of. Click on the collection name to view similar companies.

Taysha Gene Therapies Inc's Investors

Taysha Gene Therapies Inc's Industries

Medical Organizations

Health Care Companies

Biotechnology Companies

Taysha Gene Therapies Inc's Tech Stack

LOCATIONS

Where they work

Taysha Gene Therapies Inc Headquarters Location

3000 Pegasus Park Dr suite 1430, Dallas, TX, 75247

Loading map…